Reply to letter to the editor “Regarding nusinersen and other therapeutic strategies for improved motor function”

We would like to thank Pashin et al. [1] for their insightful comments on our study [2]. As shown in our study, nusinersen demonstrated treatment variability to nusinersen in patients with spinal muscular atrophy (SMA) types 2 and 3. To improve this outcome, we strongly agree that additional approaches, such as combinations or novel therapeutic strategies, should be investigated.